S. Korean firm seeks FDA nod to test stem cell drug for osteoarthritis

05/8/2013 | BioSpectrum Asia

South Korea's RNL Bio submitted an investigational new drug application to the FDA for RNL-JointStem, its adipose-based stem cell treatment for osteoarthritis. If the application is approved, the firm could begin midstage trials in the U.S. next quarter. RNL-JointStem has been tested in Phase I and II studies approved by Korean regulators.

View Full Article in:

BioSpectrum Asia

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Chief Financial Officer
B. E. Smith
Miramar, FL
Claims Director
PacificSource
Springfield, OR
Consultant
Attest Health Care Advisors
Nationwide, SL_Nationwide
Biotechnology/Pharmaceutical Patent Attorney
Coats and Bennett PLLC
Cary, NC
Sr. Regulatory Specialist, Biotech Center of Expertise
BASF, The Chemical Co.
San Diego, CA